BioCryst Pharmaceuticals to Report Q4 2025 Financial Results on February 26

BioCryst Pharmaceuticals will report its Q4 2025 financial results on February 26, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. BioCryst is a biotechnology firm focused on developing and commercializing medicines for hereditary angioedema and other rare diseases. The company has commercialized ORLADEYO, a once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics.